BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 15086696)

  • 21. High-dose therapy and autologous blood stem cell transplantation in multiple myeloma: preliminary results of a randomized trial involving 167 patients.
    Fermand JP; Ravaud P; Chevret S; Leblond V; Divine M; Dreyfus F; Belanger C; Troussard X; Mariette X; Brouet JC
    Stem Cells; 1995 Aug; 13 Suppl 2():156-9. PubMed ID: 8520505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
    Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
    Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
    Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
    Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma.
    Alici E; Björkstrand B; Treschow A; Aints A; Smith CI; Gahrton G; Dilber MS
    Cancer Gene Ther; 2007 Mar; 14(3):227-32. PubMed ID: 17082794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution.
    Magagnoli M; Castagna L; Balzarotti M; Sarina B; Timofeeva I; Bertuzzi A; Compasso S; Nozza A; Siracusano L; Santoro A
    Am J Hematol; 2003 Aug; 73(4):267-72. PubMed ID: 12879431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma.
    Lazzarino M; Corso A; Barbarano L; Alessandrino EP; Cairoli R; Pinotti G; Ucci G; Uziel L; Rodeghiero F; Fava S; Ferrari D; Fiumanò M; Frigerio G; Isa L; Luraschi A; Montanara S; Morandi S; Perego D; Santagostino A; Savarè M; Vismara A; Morra E
    Bone Marrow Transplant; 2001 Nov; 28(9):835-9. PubMed ID: 11781643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study.
    Bourhis JH; Bouko Y; Koscielny S; Bakkus M; Greinix H; Derigs G; Salles G; Feremans W; Apperley J; Samson D; Björkstrand B; Niederwieser D; Gahrton G; Pico JL; Goldschmidt H;
    Haematologica; 2007 Aug; 92(8):1083-90. PubMed ID: 17640853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    López-Pérez R; García-Sanz R; González D; Balanzategui A; Chillón MC; Alaejos I; Mateos MV; Caballero MD; Corral M; Orfão A; González M; San Miguel JF
    Bone Marrow Transplant; 2001 Oct; 28(7):665-72. PubMed ID: 11704789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma.
    Schiller G; Vescio R; Freytes C; Spitzer G; Lee M; Wu CH; Cao J; Lee JC; Lichtenstein A; Lill M; Berenson R; Berenson J
    Bone Marrow Transplant; 1998 Jan; 21(2):141-5. PubMed ID: 9489630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
    Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC
    J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
    Fermand JP; Katsahian S; Divine M; Leblond V; Dreyfus F; Macro M; Arnulf B; Royer B; Mariette X; Pertuiset E; Belanger C; Janvier M; Chevret S; Brouet JC; Ravaud P;
    J Clin Oncol; 2005 Dec; 23(36):9227-33. PubMed ID: 16275936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients.
    Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B
    Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
    Fermand JP; Ravaud P; Chevret S; Divine M; Leblond V; Belanger C; Macro M; Pertuiset E; Dreyfus F; Mariette X; Boccacio C; Brouet JC
    Blood; 1998 Nov; 92(9):3131-6. PubMed ID: 9787148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
    Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
    Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma.
    Raina V; Sharma A; Kumar R; Bhargava M
    Cancer; 1996 Mar; 77(6):1073-8. PubMed ID: 8635126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
    Shimura Y; Kuroda J; Uchiyama H; Kawata-Iida E; Tsutsumi Y; Nagoshi H; Mizutani S; Yamamoto-Sugitani M; Matsumoto Y; Kobayashi T; Horiike S; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
    J Clin Apher; 2013 Oct; 28(5):368-73. PubMed ID: 23804501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.